Henric Bjarke
2020
In 2020, Henric Bjarke earned a total compensation of $1.1M as Senior Vice President and Chief Operating Officer at Inozyme Pharma, a 83% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $187,095 |
|---|---|
| Option Awards | $506,970 |
| Salary | $389,782 |
| Total | $1,083,847 |
Bjarke received $507K in option awards, accounting for 47% of the total pay in 2020.
Bjarke also received $187.1K in non-equity incentive plan and $389.8K in salary.
Rankings
In 2020, Henric Bjarke's compensation ranked 8,300th out of 13,090 executives tracked by ExecPay. In other words, Bjarke earned more than 36.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,300 out of 13,090 | 37th |
Division Manufacturing | 3,522 out of 5,621 | 37th |
Major group Chemicals And Allied Products | 1,424 out of 2,254 | 37th |
Industry group Drugs | 1,240 out of 1,954 | 37th |
Industry Pharmaceutical Preparations | 917 out of 1,459 | 37th |
Source: SEC filing on April 27, 2021.
Bjarke's colleagues
We found two more compensation records of executives who worked with Henric Bjarke at Inozyme Pharma in 2020.